nach oben

Tumor Biology

Erschienen in:

11.02.2016 | Original Article

UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis

verfasst von: Yijun Yang, Yi Jiang, Yicong Wan, Lin Zhang, Jiangnan Qiu, Shulin Zhou, Wenjun Cheng

Erschienen in: Tumor Biology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Urothelial cancer associated 1 (UCA1) is an example of functional long noncoding RNAs involved in many biologic processes. However, little is known about the association between UCA1 expression and metastasis in epithelial ovarian cancer (EOC). Findings of this study confirmed that not only UCA1 was aberrantly upregulated in EOC tissues and cells, but also correlated with status of lymph node metastasis and FIGO stage. Furthermore, univariate and multivariate analyses showed that UCA1 was a prognostic factor for overall survival in EOC patients. In vitro, knockdown of UCA1 reduced the invasion and migration ability of EOC cells. The results showed that UCA1 could function as an endogenous sponge by directly binding to miR-485-5p. Depletion of UCA1 was involved in the downregulation of matrix metallopeptidase 14 (MMP14) expression, a target gene of miR-485-5p. In conclusion, our work indicates that UCA1 is a new prognostic biomarker for EOC, establishing a novel connection among UCA1, miR-485-5p, and MMP14 in EOC metastasis.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.CrossRefPubMed

Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28. doi:10.1038/nrc2644.CrossRefPubMedPubMedCentral

Bowtell DDL. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010;10(11):803–8. doi:10.1038/nrc2946.CrossRefPubMed

Rustin G, van der Burg M, Griffin C, Qian W, Swart AM. Early versus delayed treatment of relapsed ovarian cancer. Lancet. 2011;377(9763):380–1. doi:10.1016/s0140-6736(11)60126-8.CrossRefPubMed

Tsai M-C, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 2011;71(1):3–7. doi:10.1158/0008-5472.can-10-2483.CrossRefPubMedPubMedCentral

Huang J-L, Zheng L, Hu Y-W, Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis. 2014;35(3):507–14. doi:10.1093/carcin/bgt405.CrossRefPubMed

Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21. doi:10.1038/nrg3606.CrossRefPubMed

J-j Q, Lin Y-y, L-c Y, J-x D, W-w F, H-y J, et al. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecol Oncol. 2014;134(1):121–8. doi:10.1016/j.ygyno.2014.03.556.CrossRef

Sheng X, Li J, Yang L, Chen Z, Zhao Q, Tan L, et al. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer. Oncol Rep. 2014;32(1):277–85. doi:10.3892/or.2014.3208.PubMed

10.

Qiu J-J, Lin Y-Y, Ding J-X, Feng W-W, Jin H-Y, Hua K-Q. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. Int J Oncol. 2015;46(6):2497–505. doi:10.3892/ijo.2015.2943.PubMed

11.

Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147(2):358–69. doi:10.1016/j.cell.2011.09.028.CrossRefPubMedPubMedCentral

12.

Kallen AN, Zhou X-B, Xu J, Qiao C, Ma J, Yan L, et al. The imprinted H19 LncRNA antagonizes Let-7 MicroRNAs. Mol Cell. 2013;52(1):101–12. doi:10.1016/j.molcel.2013.08.027.CrossRefPubMed

13.

Wang K, Long B, Zhou L-Y, Liu F, Zhou Q-Y, Liu C-Y, et al. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun. 2014;5:3596. doi:10.1038/ncomms4596.PubMed

14.

Wang F, Li X, Xie X, Zhao L, Chen W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008;582(13):1919–27. doi:10.1016/j.febslet.2008.05.012.CrossRefPubMed

15.

Wang T, Yuan J, Feng N, Li Y, Lin Z, Jiang Z, et al. Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer. Tumor Biol. 2014;35(10):10075–84. doi:10.1007/s13277-014-2321-2.CrossRef

16.

Li Z, Li X, Wu S, Xue M, Chen W. Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway. Cancer Sci. 2014;105(8):951–5. doi:10.1111/cas.12461.CrossRefPubMedPubMedCentral

17.

Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q, et al. Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma. 2015;62(3):432–8. doi:10.4149/neo_2015_051.CrossRefPubMed

18.

Fu WM, Zhu X, Wang WM, Lu YF, Hu BG, Wang H, et al. Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling. J Hepatol. 2015;63(4):886–95. doi:10.1016/j.jhep.2015.05.016.CrossRefPubMed

19.

Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 2010;57(5):734–43. doi:10.1111/j.1365-2559.2010.03686.x.CrossRefPubMed

20.

Izaurralde E. Elucidating the temporal order of silencing. EMBO Rep. 2012;13(8):662–3. doi:10.1038/embor.2012.91.CrossRefPubMedPubMedCentral

21.

Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102–14. doi:10.1038/nrg2290.CrossRefPubMed

22.

Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005;123(4):631–40. doi:10.1016/j.cell.2005.10.022.CrossRefPubMed

23.

X-h L, Sun M, Nie F-q, Ge Y-b, Zhang E-b, Yin D-d, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014;13:92. doi:10.1186/1476-4598-13-92.CrossRef

24.

Wang F, Ying H-Q, He B-S, Pan Y-Q, Deng Q-W, Sun H-L, et al. Upregulated IncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015;6(10):7899–917.CrossRefPubMedPubMedCentral

25.

Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M, et al. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis. 2014;5:e1008. doi:10.1038/cddis.2013.541.CrossRefPubMedPubMedCentral

26.

H-m Z, Yang F-q, Chen S-J, Che J, Zheng J-h. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. Tumor Biol. 2015;36(4):2947–55. doi:10.1007/s13277-014-2925-6.CrossRef

27.

Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. Plos Genet. 2013;9(3):e1003368. doi:10.1371/journal.pgen.1003368.CrossRefPubMedPubMedCentral

28.

Pang E-J, Yang R, Fu X-b, Liu Y-f. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumor Biol. 2015;36(4):2403–7. doi:10.1007/s13277-014-2850-8.CrossRef

29.

Anaya-Ruiz M, Bandala C, Perez-Santos JL. miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells. Asian Pac J Cancer Prev. 2013;14(6):3757–60.CrossRefPubMed

30.

He N, Zheng H, Li P, Zhao Y, Zhang W, Song F, et al. miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. PLoS One. 2014;9(7):e102093. doi:10.1371/journal.pone.0102093.CrossRefPubMedPubMedCentral

31.

Pahwa S, Stawikowski MJ, Fields GB. Monitoring and inhibiting MT1-MMP during cancer initiation and progression. Cancers. 2014;6(1):416–35. doi:10.3390/cancers6010416.CrossRefPubMedPubMedCentral

32.

Jo Y, Yeon J, Kim HJ, Lee ST. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. Biochem J. 2000;345(Pt 3):511–9.CrossRefPubMedPubMedCentral

33.

Wang Y-z, Wu K-p, Wu A-b, Yang Z-c, J-m L, Y-l M, et al. MMP-14 overexpression correlates with poor prognosis in non-small cell lung cancer. Tumor Biol. 2014;35(10):9815–21. doi:10.1007/s13277-014-2237-x.CrossRef

34.

Udayakumar TS, Chen ML, Bair EL, von Bredow DC, Cress AE, Nagle RB, et al. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta 3 chain and induces cell migration. Cancer Res. 2003;63(9):2292–9.PubMed

35.

Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer. 2003;106(6):848–55. doi:10.1002/ijc.11313.CrossRefPubMed

36.

Wang L, Yuan J, Tu Y, Mao X, He S, Fu G, et al. Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma. Clin Transl Oncol. 2013;15(2):139–45. doi:10.1007/s12094-012-0900-5.CrossRefPubMed

37.

Albrechtsen R, Kveiborg M, Stautz D, Vikesa J, Noer JB, Kotzsh A, et al. ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth. J Cell Sci. 2013;126(Pt 20):4707–20. doi:10.1242/jcs.129510.CrossRefPubMed

38.

Yang C, Li X, Wang Y, Zhao L, Chen W. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through P13-K dependent pathway in bladder carcinoma cells. Gene. 2012;496(1):8–16. doi:10.1016/j.gene.2012.01.012.CrossRefPubMed

39.

Cai Y, Yu X, Hu S, Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 2009;7(4):147–54. doi:10.1016/s1672-0229(08)60044-3.CrossRefPubMed

Titel: UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis
verfasst von: Yijun Yang
Yi Jiang
Yicong Wan
Lin Zhang
Jiangnan Qiu
Shulin Zhou
Wenjun Cheng
Publikationsdatum: 11.02.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 8/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4917-1

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis

Abstract

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status

Diallyl disulfide induces apoptosis and autophagy via mTOR pathway in myeloid leukemic cell line

Long non-coding RNA AK027294 involves in the process of proliferation, migration, and apoptosis of colorectal cancer cells

miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1

Oligoesculin fraction induces anti-tumor effects and promotes immune responses on B16-F10 mice melanoma

Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie